Ness Ziona, Israel
Ness Ziona, Israel

Time filter

Source Type

The present invention relates to pharmaceutical suspensions comprising multimeric- multiepitope influenza polypeptides, to processes for their production and to their use as immunizing subjects against influenza. In particular, the invention relates to stable aqueous microparticulate suspensions comprising a multimeric multiepitope polypeptide.


Dublin, April 18, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Seasonal Influenza Vaccine Market Size, Country Outlook, Vaccination Analysis, Pipeline Insights, Clinical Trials Statement, Deals Type, Regulatory, Price Trends, Competitive Strategies and Forecast, 2016 to 2022" drug pipelines to their offering. Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against seasonal influenza, introduction of quadrivalent influenza vaccines, increase in the size of the elderly population in most countries. The barriers limiting the growth of the influenza market include limited patient awareness regarding the threat of influenza and the importance of influenza vaccinations, high investment and strict regulations act as barriers for new entrants. Further, prudent analysis has been done on the competitor's part, where three major players grab major share of the seasonal influenza vaccine market by revenue. Sanofi Pasteur, GlaxoSmithKline(GSK), Seqirus, AstraZeneca and Protein Sciences Corporation are the key influencers with their products in the seasonal influenza vaccine market. Other emerging players such as Novavax, Daiichi-Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period. The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projection using a suitable set of assumptions and methodologies. It provides essential insights into seasonal influenza vaccine sales forecasts for the top seven countries, comprising the US, the UK, France, Italy, Spain, Germany and Japan until 2022. It also covers vaccination patterns and geographic distribution and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials, pipeline and promising vaccines in seasonal influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details. The report concludes with the profiles of major players in the seasonal influenza vaccine market such as Sanofi Pasteur, GSK, Sequirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook, and sales analysis of seasonal influenza vaccine market from 2011 to 2022. The report also entails major drivers and barriers of seasonal influenza vaccine market. Seven Major Markets(7MM) covered in the report are as follows: 1. United States 2. United Kingdom 3. France 4. Italy 5. Spain 6. Germany 7. Japan Major and Promising Vaccines covered in the report are as follows: 1. Fluzone High-Dose 2. Fluzone Quadrivalent 3. Intradermal (ID) Trivalent 4. Vaxigrip 5. Fluarix Quadrivalent 6. Flulaval Quadrivalent 7. Fluenz Tetra 8. FluMist Quadrivalent 9. Flublok 10. VN-100 11. M-001 12. VAX-2012Q 13. TAK-850 14. Flucelvax Quadrivalent 15. Afluria Quadrivalent 16. Agrippal 17. Fluad 18. Fluvirin 19. Fluvax Seasonal Influenza Vaccine Report is segmented into 10 points: 1: Introduction with Executive Summary 2: Forecasts data for the seasonal influenza vaccine market in the top seven countries. This point is divided into 4 segments. - Overall seasonal influenza vaccine market data from 2010 to 2022 - Overall number of persons vaccinated with seasonal influenza vaccine data from 2010 to 2022 - Seasonal influenza vaccine market share in the top seven countries data from 2010 to 2022 - Persons being vaccinated with influenza vaccine share in the top seven countries data from 2010 to 2022 3: Key market drivers and barriers in the seasonal influenza vaccine market 4: Detailed recent and forecasts for the seasonal influenza vaccine markets in the US, the UK, France, Italy, Spain, Germany and Japan, comprising of market size, total number of persons vaccinated, number of children vaccinated, number of 60+ years of age persons vaccinated, number of pregnant women vaccinated, number of chronic medical condition persons vaccinated, number of healthcare workers vaccinated and vaccination coverage 5: Detailed information on seasonal influenza vaccine production & distribution in United States. The information includes vaccine choices remain available for patients, providers, prices of a dose of vaccine, production, supply, and allocation by the major seasonal influenza vaccine manufacturers, seasonal influenza vaccine distribution & demand, seasonal influenza vaccine effectiveness, managing influenza with diagnostic resources, distribution method of seasonal influenza vaccination 6: Information about regulatory landscape including the approval process and an overview of the regulatory authorities in the United States, EU and Japan 7: Key M&A deals that took place in the seasonal influenza vaccine market between 2003 and 2015 and lists the major collaborations, licensing, exclusive and distribution agreements deals 8: Detailed pipeline influenza vaccines in various companies' pipelines with clinical development and early stage development vaccines 9: Detailed information of the recruiting clinical trials statement by phase, trial status, study sponsor name and study phase 10: Information on the key players in the market with business overview, product outlook and sales analysis of the seasonal influenza vaccine For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/jc66pd/seasonal


News Article | May 30, 2017
Site: www.prnewswire.com

Results are in New Israel Shekels (NIS) and convenience translation to $US is provided using the exchange rate of 3.63 (NIS/$US) as at March 31, 2017. As of March 31, 2017, BiondVax had cash and cash equivalents, short-term investments and marketable securities of NIS 35 million ($9.6 million) as compared to NIS 27 million as of December 31, 2016. The increase is attributable to a private placement of NIS 10.9 million. BiondVax is a biopharmaceutical company developing a universal flu vaccine. The vaccine is designed to provide multi-season protection against most seasonal and pandemic human influenza virus strains. BiondVax's proprietary technology utilizes a unique combination of conserved and common peptides from influenza virus proteins, activating both arms of the immune system for a cross-protecting and long-lasting effect. BiondVax is traded on NASDAQ: BVXV and TASE: BVXV. For more information, please visit www.biondvax.com. This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve certain risks and uncertainties reflect the management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. risks and uncertainties include, but are not limited to, the risk that drug development involves a lengthy and expensive process with uncertain outcome, the results of the contemplated  Phase 2 & 3 trials, delays or obstacles in launching and/or successfully completing our clinical trials, the impact of the global economic environment on the Company customer target base, the adequacy of available cash resource and the ability to raise capital when needed. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2016 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, www.sec.gov, and in the Company's periodic filings with the SEC and the Tel-Aviv Stock Exchange. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biondvax-announces-first-quarter-2017-financial-results-and-update-300465204.html


Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.2.3.0-1 | Award Amount: 7.82M | Year: 2013

UNISEC brings together a European consortium of 3 University partners, 5 National Health Institutes and 4 SMEs, all with leading expertise in influenza vaccine research and development, to work on promising recently developed concepts for a universal influenza vaccine. The consortium is exceptionally strong, interdisciplinary and intersectional in nature, and encompasses a unique combination of scientific and technological expertise from lead identification to clinical trial execution. UNISEC will bring a number of vaccine concepts together into a single study in order to identify, develop and clinically test the 3 most promising leads for a universal influenza vaccine, which must (1) demonstrate adequate (universal) protection, and (2) be technically suitable for development to a marketable product. Preclinical and clinical methodologies will be developed allowing a comparative evaluation of the vaccine concepts. Head-to-head comparisons in animal models will also be performed, with the most promising concepts to then be ready for clinical assessment. Independent comparative clinical studies will be executed and carried out by 5 established Clinical Trial Site partners. The expected impact of the UNISEC work programme will be the resolution of current problems of non-uniformity in the development and evaluation of universal influenza vaccines in Europe by a unified approach using an expert and sustainable vaccine expertise network. The UNISEC results will directly contribute to a timely, longer-term, broader, more effective and cost-effective universal influenza vaccine for the prevention of annual and pandemic influenza. The success of UNISEC will be based on the leading experience of its consortium partners; the proven track record of its clinical trial site partners; and a coherent and well-defined management structure and dissemination program, underpinned by the fact that several UNISEC partners were previously part of the successful EU FLUSECURE project.


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Influenza Vaccines Market in Top 5 European Countries to 2022 - Market Size, Development and Forecasts" report to their offering. The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projection using a suitable set of assumptions and methodologies. It provides essential insights into influenza vaccine sales forecast for the top five countries, comprising the UK, France, Italy, Spain and Germany until 2022. Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against Influenza, introduction of quadrivalent influenza vaccines, increase in the size of the elderly population in most countries. Prudent analysis has been done on the competitor's part, where three major players grab major share of the influenza vaccine market by revenue. Sanofi Pasteur, GlaxoSmithKline (GSK), Seqirus, AstraZeneca and Protein Sciences Corporation are the key influencers with their products in the influenza vaccine market. Other emerging players such as Novavax, Daiichi-Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period. It also covers vaccination patterns and geographic distribution and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials, pipeline and promising vaccines in influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details. The report concludes with the profiles of major players in the influenza vaccine market, such as Sanofi Pasteur, GSK, Sequirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook and sales analysis of influenza vaccine market from 2011 to 2022. The report also entails major drivers and barriers of influenza vaccine market. Major and Promising Vaccines covered in the report are as follows: Key Companies Covered in the Report are as follows: For more information about this report visit http://www.researchandmarkets.com/research/n7tsqb/influenza


Research and Markets has announced the addition of the "Influenza Vaccines Market in Top 5 European Countries to 2022 - Market Size, Development and Forecasts" report to their offering. The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projection using a suitable set of assumptions and methodologies. It provides essential insights into influenza vaccine sales forecast for the top five countries, comprising the UK, France, Italy, Spain and Germany until 2022. Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against Influenza, introduction of quadrivalent influenza vaccines, increase in the size of the elderly population in most countries. Prudent analysis has been done on the competitor's part, where three major players grab major share of the influenza vaccine market by revenue. Sanofi Pasteur, GlaxoSmithKline(GSK), Seqirus, AstraZeneca and Protein Sciences Corporation are the key influencers with their products in the influenza vaccine market. Other emerging players such as Novavax, Daiichi-Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period. It also covers vaccination patterns and geographic distribution and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials, pipeline and promising vaccines in influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details. The report concludes with the profiles of major players in the influenza vaccine market, such as Sanofi Pasteur, GSK, Sequirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook and sales analysis of influenza vaccine market from 2011 to 2022. The report also entails major drivers and barriers of influenza vaccine market. Major and Promising Vaccines covered in the report are as follows: 1. Fluzone High-Dose 2. Fluzone Quadrivalent 3. Intradermal (ID) Trivalent 4. Vaxigrip 5. Fluarix Quadrivalent 6. Flulaval Quadrivalent 7. Fluenz Tetra 8. FluMist Quadrivalent 9. Flublok 10. VN-100 11. M-001 12. VAX-2012Q 13. TAK - 850 14. Flucelvax Quadrivalent 15. Afluria Quadrivalent 16. Agrippal 17. Fluad 18. Fluvirin 19. Fluvax Key Companies Covered in the Report are as follows: 1. Sanofi Pasteur 2. GlaxoSmithKline(GSK) 3. Seqirus 4. AstraZenecca 5. Protein Sciences Corporation 6. Novavax 7. Daiichi-Sankyo 8. Mitsubishi Tanabe Pharma 9. BiondVax Pharmaceuticals Ltd 10. VaxInnate Key Topics Covered: 1. Executive Summary 2. Influenza Vaccine Market in Top 5 European Countries - Market Overview 3. Influenza Vaccine Market Drivers and Barriers 4. Influenza Vaccine Market in Top 5 European Countries - Geographical Landscape 5. European Union Influenza Vaccine Market - Regulatory Landscape 6. Market Dynamics - Mergers, Acquisitions, Key Agreements & Collaborations 7. Influenza Vaccine - Pipeline Assessment 8. Influenza Vaccine - Clinical Trials Assessment by Phase and Trial Status 9. Key Companies Analysis For more information about this report visit http://www.researchandmarkets.com/research/hcj3f7/influenza Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716


Gottlieb T.,BiondVax | Ben-Yedidia T.,BiondVax
Journal of Autoimmunity | Year: 2014

The development of vaccines has been one of the most important contributions of immunology to public health to date. Although several infectious diseases have all but vanished thanks to effective vaccines, the most common infectious disease, influenza, still represents a major threat to public health. This is more concerning than ever before in light of potentially virulent avian pandemic strains which have emerged in the last decade and infected human hosts, causing high morbidity and mortality. Despite considerable efforts to improve production of influenza vaccines and vaccinate large portions of the population annually, the currently available influenza vaccines are strain-specific and not effective enough. Considering the vulnerability of infants and elderly to seasonal influenza-related complications and the ever present public health threat of a deadly influenza pandemic, there is urgent need for a new kind of influenza vaccine. Ideally, such a vaccine should provide enhanced long term, multi-strain protection without compromising safety and in this way, dramatically improve global protection against seasonal and pandemic influenza viruses. This review highlights one approach to developing a universal influenza vaccine, which is based on highly conserved viral sequences, 'epitopes', that specifically activate humoral and/or cellular immune responses. This approach to vaccinology was pioneered by Prof Arnon, who initiated development of an epitope-based universal vaccine called Multimeric-001 (M-001), which has already been validated in clinical trials to induce broad immunity against A and B-Type, seasonal and pandemic strains. © 2014 Elsevier Ltd. All rights reserved.


NESS ZIONA, Israel, November 29, 2016 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV) today announced positive preliminary safety results from its European Phase 2b clinical trial of M-001, its universal flu vaccine candidate. The trial is designed to compa...


Patent
BiondVax | Date: 2014-04-28

An isolated polynucleotide encoding an influenza multi-epitope polypeptide, wherein the multi-epitope polypeptide comprises multiple copies of a plurality of influenza virus peptide epitopes wherein the polypeptide is B(X_(1)ZX_(2)Z . . . X_(m))_(n)B or B(X_(1))_(n)Z(X_(2))_(n)Z . . . (X_(m))_(n)B; wherein B is an optional sequence of 1-4 amino acid residues; n is at each occurrence independently an integer of 2-50; m is an integer of 3-15; each of X_(1), X_(2 ). . . X_(m )is an influenza peptide epitope of 4-24 amino acid residues; and Z at each occurrence is a bond or a spacer of 1-4 amino acid residues.


The present invention relates to use of multimeric multi-epitope peptide-based compositions for immunizing subjects against influenza by administering the compositions to the subject prior to or together with seasonal or pandemic influenza vaccines. The present invention also relates to compositions that include a multimeric multi-epitope polypeptide and a seasonal or pandemic preparation against influenza.

Loading BiondVax collaborators
Loading BiondVax collaborators